AllAnalyst Report
logoMorningstarApril 16, 2021

Smith & Nephew plc: Under Pressure From the Pandemic, Smith & Nephew Set for Improvement in 2021

Symbols
SNN
Sector(s)
Healthcare
Rating
Current Price
$42.89
Fair Value
Economic Moat
Stewardship

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and ENT technologies, and wound-care solutions. Slightly more than 40% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 27% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Quotes from this report
Symbol
NamePriceIndustryCurrencyMarket CapMorningstar RatingEconomic MoatUncertainty RatingFair ValuePrice/Fair Value
SNN
Smith & Nephew SNATS, Inc.42.89N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Profile

Debbie Wang

Senior Equity Analyst
Debbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.